Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. NAVN
9. DFTX
10. IBM

Go back to Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

Ironwood Pharma (IRWD) Misses Q2 EPS by $6.96; Offers FY23 Revenue Guidance

August 8, 2023 7:09 AM EDT

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($6.71), $6.96 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $107.38 million versus the consensus estimate of $103.57 million.

GUIDANCE:

Ironwood Pharma sees FY2023 revenue of $435-450 million, versus the consensus of... More